Measles Vaccine Patches: Could They Improve Access?

How could vaccine patches make immunization easier?

In its January 5 outlook, Gavi highlighted patch-based delivery among the vaccine technologies worth watching. The appeal extends beyond avoiding conventional injections: an easier delivery method could help vaccination services reach children who miss routine appointments. This was an expert assessment of promising developments, rather than an announcement that measles patches were ready for routine use. [Gavi's vaccine innovation outlook](https://www.gavi.org/vaccineswork/what-are-biggest-vaccine-breakthroughs-coming-2026-we-asked-six-experts).

Microarray patches place vaccine into the outer layers of skin using microscopic projections. WHO identifies several potential advantages, including eliminating the need to mix vaccine before administration, avoiding conventional needles and syringes, and simplifying delivery. Greater heat stability could also ease refrigeration requirements, but storage advantages must be demonstrated for each product. These features could make outreach vaccination more practical where maintaining equipment and transporting supplies are difficult. [WHO's overview of measles–rubella microarray patches](https://www.who.int/news-room/articles-detail/2023-November-132).

What did the measles vaccine patch trial find?

The phase 1/2 trial published in The Lancet enrolled 45 adults, 120 toddlers and 120 infants in The Gambia. Among infants with evaluable results, 93% receiving the patch developed a measles antibody response, compared with 90% receiving an injection; both groups reached 100% for rubella. These percentages describe seroconversion, a laboratory measure of immune response, rather than observed prevention of infection. [Adigweme and colleagues' randomized trial](https://pmc.ncbi.nlm.nih.gov/articles/PMC11099471/).

Researchers collected unsolicited adverse events through day 180. Patch-site reactions, including firmness and discoloration, occurred, but local reactions were mild and no related severe or serious adverse events were reported. The study's size limits conclusions about rare harms, while its antibody findings cannot establish how effectively patches would prevent outbreaks. The Gates Foundation funded the research, and several authors disclosed affiliations with patch developer Micron Biomedical. [Trial results and disclosures](https://pmc.ncbi.nlm.nih.gov/articles/PMC11099471/).

What must happen before vaccine patches reach routine care?

WHO's development framework identifies questions extending beyond whether a patch generates antibodies. Developers must establish consistent manufacturing, an appropriate safety profile and evidence supporting regulatory and vaccination-policy decisions. Health services also need to understand how patches perform in their intended delivery settings. A product that works under trial conditions still needs dependable supply, suitable training and clear procedures for routine use. [WHO's development and implementation priorities](https://www.who.int/news-room/articles-detail/2023-November-132).

For families, research into easier delivery does not provide a reason to postpone established vaccination. WHO recommends that national programs reach all children with two doses of measles-containing vaccine. Parents can ask their vaccination service to check records and arrange missed doses under the local schedule. Any future patch program would need clear guidance on which infections its product covers and how it fits existing schedules. [WHO's measles vaccination guidance](https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/measles).